Condition (MeSH)
Kwashiorkor
ClinicalTrials.gov lists 45 trials for Kwashiorkor or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
45 of the 45 trials are tagged with Kwashiorkor itself; the rest are tagged with a narrower condition beneath it.
When did Kwashiorkor trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 5 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 6 |
| 2019 | 4 |
| 2018 | 3 |
| 2017 | 2 |
| 2016 | 1 |
| 2014 | 3 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 15 months across 32 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Kwashiorkor trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2/3 | 2 |
| Phase 3 | 2 |
| Not applicable | 30 |
| Observational | 11 |
How many Kwashiorkor trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 32 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Kwashiorkor? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Amoxicillin | 4 |
| Cefdinir | 1 |
| Albendazole | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| protein supplement | 2 |
| Control (placebo) group | 1 |
| Pyrimethamine/sulfadoxine | 1 |
| Resource Maltodextrin | 1 |
| Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP) | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Kwashiorkor? (23)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy. | Science translational medicine | 2015 | Yes |
| Effects of randomized supplementation of methionine or alanine on cysteine and glutathione production during the early phase of treatment of children with edematous malnutrition. | The American journal of clinical nutrition | 2014 | Yes |
| Impaired cardiovascular structure and function in adult survivors of severe acute malnutrition. | Hypertension (Dallas, Tex. : 1979) | 2014 | Yes |
| Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. | Science (New York, N.Y.) | 2013 | Yes |
| Prenatal factors contribute to the emergence of kwashiorkor or marasmus in severe undernutrition: evidence for the predictive adaptation model. | PloS one | 2012 | Yes |
Showing 5 of 23 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.